Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy

Jonathan Wall, Angela D. Williams, James S. Foster, Tina Richey, Alan Stuckey, Sallie Macy, Craig Wooliver, Shawn R. Campagna, Eric D. Tague, Abigail T. Farmer, Ronald Lands, Emily Martin, Robert Heidel, Stephen Kennel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Amyloidosis is a malignant pathology associated with the formation of proteinaceous amyloid fibrils that deposit in organs and tissues, leading to dysfunction and severe morbidity. More than 25 proteins have been identified as components of amyloid, but the most common form of systemic amyloidosis is associated with the deposition of amyloid composed of Ig light chains (AL). Clinical management of amyloidosis focuses on reducing synthesis of the amyloid precursor protein. However, recently, passive immunotherapy using amyloid fibril-reactive antibodies, such as 11-1F4, to remove amyloid from organs has been shown to be effective at restoring organ function in patients with AL amyloidosis. However, 11-1F4 does not bind amyloid in all AL patients, as evidenced by PET/CT imaging, nor does it efficiently bind the many other forms of amyloid. To enhance the reactivity and expand the utility of the 11-1F4 mAb as an amyloid immunotherapeutic, we have developed a pretargeting "peptope" comprising a multiamyloid-reactive peptide, p5+14, fused to a high-affinity peptide epitope recognized by 11-1F4. The peptope, known as p66, bound the 11-1F4 mAb in vitro with subnanomolar efficiency, exhibited multiamyloid reactivity in vitro and, using tissue biodistribution and SPECT imaging, colocalized with amyloid deposits in a mouse model of systemic serum amyloid A amyloidosis. Pretreatment with the peptope induced 11-1F4 mAb accumulation in serum amyloid A deposits in vivo and enhanced 11-1F4-mediated dissolution of a human AL amyloid extract implanted in mice.

Original languageEnglish (US)
Pages (from-to)E10839-E10848
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number46
DOIs
StatePublished - Nov 13 2018

Fingerprint

Amyloid
Peptides
Amyloidosis
Antibodies
Amyloid Plaques
Serum Amyloid A Protein
Therapeutics
Passive Immunization
Amyloid beta-Protein Precursor
Single-Photon Emission-Computed Tomography
Epitopes
Pathology
Morbidity
Light

All Science Journal Classification (ASJC) codes

  • General

Cite this

Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. / Wall, Jonathan; Williams, Angela D.; Foster, James S.; Richey, Tina; Stuckey, Alan; Macy, Sallie; Wooliver, Craig; Campagna, Shawn R.; Tague, Eric D.; Farmer, Abigail T.; Lands, Ronald; Martin, Emily; Heidel, Robert; Kennel, Stephen.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 46, 13.11.2018, p. E10839-E10848.

Research output: Contribution to journalArticle

Wall, Jonathan ; Williams, Angela D. ; Foster, James S. ; Richey, Tina ; Stuckey, Alan ; Macy, Sallie ; Wooliver, Craig ; Campagna, Shawn R. ; Tague, Eric D. ; Farmer, Abigail T. ; Lands, Ronald ; Martin, Emily ; Heidel, Robert ; Kennel, Stephen. / Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. In: Proceedings of the National Academy of Sciences of the United States of America. 2018 ; Vol. 115, No. 46. pp. E10839-E10848.
@article{94bd69a7675e41599adde83c01e7ff55,
title = "Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy",
abstract = "Amyloidosis is a malignant pathology associated with the formation of proteinaceous amyloid fibrils that deposit in organs and tissues, leading to dysfunction and severe morbidity. More than 25 proteins have been identified as components of amyloid, but the most common form of systemic amyloidosis is associated with the deposition of amyloid composed of Ig light chains (AL). Clinical management of amyloidosis focuses on reducing synthesis of the amyloid precursor protein. However, recently, passive immunotherapy using amyloid fibril-reactive antibodies, such as 11-1F4, to remove amyloid from organs has been shown to be effective at restoring organ function in patients with AL amyloidosis. However, 11-1F4 does not bind amyloid in all AL patients, as evidenced by PET/CT imaging, nor does it efficiently bind the many other forms of amyloid. To enhance the reactivity and expand the utility of the 11-1F4 mAb as an amyloid immunotherapeutic, we have developed a pretargeting {"}peptope{"} comprising a multiamyloid-reactive peptide, p5+14, fused to a high-affinity peptide epitope recognized by 11-1F4. The peptope, known as p66, bound the 11-1F4 mAb in vitro with subnanomolar efficiency, exhibited multiamyloid reactivity in vitro and, using tissue biodistribution and SPECT imaging, colocalized with amyloid deposits in a mouse model of systemic serum amyloid A amyloidosis. Pretreatment with the peptope induced 11-1F4 mAb accumulation in serum amyloid A deposits in vivo and enhanced 11-1F4-mediated dissolution of a human AL amyloid extract implanted in mice.",
author = "Jonathan Wall and Williams, {Angela D.} and Foster, {James S.} and Tina Richey and Alan Stuckey and Sallie Macy and Craig Wooliver and Campagna, {Shawn R.} and Tague, {Eric D.} and Farmer, {Abigail T.} and Ronald Lands and Emily Martin and Robert Heidel and Stephen Kennel",
year = "2018",
month = "11",
day = "13",
doi = "10.1073/pnas.1805515115",
language = "English (US)",
volume = "115",
pages = "E10839--E10848",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "46",

}

TY - JOUR

T1 - Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy

AU - Wall, Jonathan

AU - Williams, Angela D.

AU - Foster, James S.

AU - Richey, Tina

AU - Stuckey, Alan

AU - Macy, Sallie

AU - Wooliver, Craig

AU - Campagna, Shawn R.

AU - Tague, Eric D.

AU - Farmer, Abigail T.

AU - Lands, Ronald

AU - Martin, Emily

AU - Heidel, Robert

AU - Kennel, Stephen

PY - 2018/11/13

Y1 - 2018/11/13

N2 - Amyloidosis is a malignant pathology associated with the formation of proteinaceous amyloid fibrils that deposit in organs and tissues, leading to dysfunction and severe morbidity. More than 25 proteins have been identified as components of amyloid, but the most common form of systemic amyloidosis is associated with the deposition of amyloid composed of Ig light chains (AL). Clinical management of amyloidosis focuses on reducing synthesis of the amyloid precursor protein. However, recently, passive immunotherapy using amyloid fibril-reactive antibodies, such as 11-1F4, to remove amyloid from organs has been shown to be effective at restoring organ function in patients with AL amyloidosis. However, 11-1F4 does not bind amyloid in all AL patients, as evidenced by PET/CT imaging, nor does it efficiently bind the many other forms of amyloid. To enhance the reactivity and expand the utility of the 11-1F4 mAb as an amyloid immunotherapeutic, we have developed a pretargeting "peptope" comprising a multiamyloid-reactive peptide, p5+14, fused to a high-affinity peptide epitope recognized by 11-1F4. The peptope, known as p66, bound the 11-1F4 mAb in vitro with subnanomolar efficiency, exhibited multiamyloid reactivity in vitro and, using tissue biodistribution and SPECT imaging, colocalized with amyloid deposits in a mouse model of systemic serum amyloid A amyloidosis. Pretreatment with the peptope induced 11-1F4 mAb accumulation in serum amyloid A deposits in vivo and enhanced 11-1F4-mediated dissolution of a human AL amyloid extract implanted in mice.

AB - Amyloidosis is a malignant pathology associated with the formation of proteinaceous amyloid fibrils that deposit in organs and tissues, leading to dysfunction and severe morbidity. More than 25 proteins have been identified as components of amyloid, but the most common form of systemic amyloidosis is associated with the deposition of amyloid composed of Ig light chains (AL). Clinical management of amyloidosis focuses on reducing synthesis of the amyloid precursor protein. However, recently, passive immunotherapy using amyloid fibril-reactive antibodies, such as 11-1F4, to remove amyloid from organs has been shown to be effective at restoring organ function in patients with AL amyloidosis. However, 11-1F4 does not bind amyloid in all AL patients, as evidenced by PET/CT imaging, nor does it efficiently bind the many other forms of amyloid. To enhance the reactivity and expand the utility of the 11-1F4 mAb as an amyloid immunotherapeutic, we have developed a pretargeting "peptope" comprising a multiamyloid-reactive peptide, p5+14, fused to a high-affinity peptide epitope recognized by 11-1F4. The peptope, known as p66, bound the 11-1F4 mAb in vitro with subnanomolar efficiency, exhibited multiamyloid reactivity in vitro and, using tissue biodistribution and SPECT imaging, colocalized with amyloid deposits in a mouse model of systemic serum amyloid A amyloidosis. Pretreatment with the peptope induced 11-1F4 mAb accumulation in serum amyloid A deposits in vivo and enhanced 11-1F4-mediated dissolution of a human AL amyloid extract implanted in mice.

UR - http://www.scopus.com/inward/record.url?scp=85056502731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056502731&partnerID=8YFLogxK

U2 - 10.1073/pnas.1805515115

DO - 10.1073/pnas.1805515115

M3 - Article

VL - 115

SP - E10839-E10848

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 46

ER -